London, UK (PRWEB) July 06, 2015
The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value of more than USD 5.58 billion in 2014. It is expected to grow at a CAGR of over 3.2 percent in the years to come to hit the USD 6.9 billion mark by 2021.
The growth is likely to be mainly spurred by an anticipated launch of a number of promising pipeline candidates and an increase in the patient population.
Higher demand for lower-priced alternatives instead of branded drugs in such countries as India and China represent one of key barriers to further growth of the regional marketplace.
The new market research report “Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs” drawn up by GBI Research is now available at MarketPublishers.com.
Title: Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
Published: May, 2015
Price: US$ 4,995.00
The research study offers insightful examination of the APAC rheumatoid arthritis therapeutics marketplace, with a special focus made on China, Australia, India and Japan. The report contains a through overview of the market, including valuable details on its background. The study discloses information on marketed products and concentrates on the product pipeline. It sheds light on the latest deals in the marketplace and forecasts market development trends up to 2021.
- comprehensive overview of the marketplace;
- insightful discussion of drug combinations that are used to treat rheumatoid arthritis;
- coverage of the pipeline for OC therapies;
- details on pipeline drug clinical trials;
- investigation of market growth drivers and barriers;
- future outlook;
- and more.
More new market research reports by the publisher can be found at GBI Research page.